We are studying the effectiveness of golcadomide in patients with relapsed or refractory large B-cell lymphoma in the brain. The goal is to see if it can help achieve remission and improve overall health.
Health conditions and diseases that the clinical trial is designed to study and treat.
Diffuse Large B-Cell Lymphoma (DLBCL) is a fast-growing type of non-Hodgkin lymphoma that affects B-cells, a type of white blood cell. It can cause symptoms like swollen lymph nodes, fever, night sweats, and unexplained weight loss.
Secondary Central Nervous System Lymphoma occurs when lymphoma spreads to the brain or spinal cord, leading to neurological symptoms. It can cause headaches, confusion, and seizures.
This condition refers to the return of primary large B-cell lymphoma in the central nervous system after treatment. Symptoms may include neurological deficits and changes in mental status.
Refractory Primary Large B-Cell Lymphoma of the CNS is a type of lymphoma that does not respond to initial treatment. It can lead to persistent symptoms and requires alternative treatment strategies.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.